This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a ...

Janux Therapeutics' lead drug, JANX007, shows promising prostate cancer results with no serious side effects. Find out why ...

RBC Capital analyst Gregory Renza maintained a Buy rating on MannKind (MNKD – Research Report) on April 3 and set a price target of $10.00. The ...

In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

The Dow Jones Industrial Average has lagged behind its flashier cousin, the S&P 500 index, in recent years, James Glassman ...

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

Dip-buying absent in early NY trading, Wall Street deep in red as trade war fears escalate despite strong jobs report.

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

The tariffs aim to correct the trade deficit, which was $918 billion in 2024, by encouraging domestic production and reducing reliance on imports. Companies like Apple may avoid tariffs by investing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...